Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
Ceftazidime/avibactam
KPC
KPC-producing K. pneumoniae
Klebsiella pneumoniae carbapenemase
Monte Carlo simulation
Pharmacokinetic/pharmacodynamic
Journal
Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
31
03
2021
revised:
15
07
2021
accepted:
31
07
2021
pubmed:
25
8
2021
medline:
30
12
2021
entrez:
24
8
2021
Statut:
ppublish
Résumé
The objective of this study was to evaluate the efficacy of different dosing regimens of ceftazidime/avibactam (CZA) in patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) pulmonary infections. A total of 70 KPC-Kp strains were isolated from sputum and bronchoalveolar lavage samples of patients with pulmonary infections in three hospitals in northern China from April 2015 to October 2015. Monte Carlo simulation (MCS) was performed using population pharmacokinetic parameters of CZA combined with the minimum inhibitory concentration (MIC) distributions gained from antimicrobial susceptibility testing to predict the efficacy of different dosing regimens. Various CZA dosing regimens were modelled using MCS. The in vitro study showed potent activity of CZA against KPC-Kp strains with MIC This study indicated that the recommended dose of CZA can provide adequate pharmacodynamic exposure for treating KPC-Kp pneumonia.
Identifiants
pubmed: 34428596
pii: S2213-7165(21)00190-9
doi: 10.1016/j.jgar.2021.07.020
pii:
doi:
Substances chimiques
Azabicyclo Compounds
0
Bacterial Proteins
0
Drug Combinations
0
avibactam, ceftazidime drug combination
0
avibactam
7352665165
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-71Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.